



# BLOOD & MARROW TRANSPLANT CLINICAL TRIALS NETWORK

20+ Years of Collaborative Research



**Mission:**  
**Evaluate promising transplantation and cellular therapies in multi-institutional clinical studies designed to improve the outcomes of patients facing life-threatening blood disorders**

**Improving Therapy. Saving Lives.**


# BMT CTN Data and Coordinating Center Leadership


- Principal Investigator, MCW  
Scientific Director Emeritus, CIBMTR  
Deputy Cancer Center Director, MCW
  - Mary Horowitz, MD, MS
- Co-Principal Investigator, NMDP  
Chief Medical Officer
  - Steve Devine, MD
- Co-Principal Investigator, Emmes  
Vice President
  - Adam Mendizabal, PhD
- Senior Statistician, MCW  
Chief, Division of Biostatistics, MCW
  - Brent Logan, PhD



# BMT CTN Data and Coordinating Center Leadership

- Principal Protocol Officer &  
CIBMTR Scientific Director
  - Mehdi Hamadani, MD
- Project Director, Emmes
  - Iris Gersten, MS
- Program Manager, CIBMTR
  - Amy Foley, MA







# BMT CTN Trials Developed in Years 1-10

2001 2002  
Developed  
Infrastructure




- = Enrollment/follow-up complete
- = Enrollment complete; ongoing F/U
- = Enrollment on-going



**PUBLICATIONS**

- ★ Primary Outcome
- ★ Safety, Secondary Outcome, or Design






# BMT CTN Trials Developed in Years 11-21




- 58 Trials Opened; 9 currently open
- 47 BMT CTN-led; 11 NCI Group/PI-led (+)
- 3 released to sites/in development:
  - 1901 Myeloma CAR T Cell: High Risk
  - 2001 Williams Gene Therapy SCD
  - 2002 Acute GVHD Treatment-TGuard2

## PUBLICATIONS

- ★ Primary Outcome
- ★ Safety, Secondary Outcome, or Design




- = Enrollment/follow-up complete
- = Enrollment complete; ongoing F/U
- = Enrollment on-going




# BMT CTN Centers

>125 centers have enrolled >15,800 patients since 2003



# BMT CTN Yearly and Cumulative Accrual to all Protocols, 2004-2021 >15,800 patients





# BMT CTN: Addressing Important Issues in HCT

	Number of Studies	Number of Publications
GVHD Prevention, Treatment and Biology	12	27
Graft Sources for HCT	10	18
Conditioning/Maintenance/Comparison to non-HCT	10	17
Rare and Non-Malignant Diseases	10	9
Most Studies Include Assessments of Quality of Life, Biomarkers, Biology		

## ORIGINAL ARTICLE

# Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy, M.D., Kouros Owzar, Ph.D., Craig C. Hofmann, M.D., David D. Hurd, M.D., Hani Hassoun, M.D., Paul G. Richardson, M.D., Sergio Giralt, M.D., Edward A. Stadtmauer, M.D., Daniel J. Weinstock, M.D.

## Regular Article

## CLINICAL TRIALS AND OBSERVATIONS

## Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia: Genomic Evidence of Residual Disease

Christopher S. Hourigan, DM, DPhil<sup>1</sup>; Laura W. Dillon, PhD<sup>1</sup>; Gege Gui, ScM<sup>1</sup>; Brent R. Logan, PhD<sup>2</sup>; Mi Jack Ghannam, BS<sup>1</sup>; Yuesheng Li, PhD<sup>1</sup>; Abel Licon, MS<sup>3</sup>; Edwin P. Alyea, MD<sup>4</sup>; Asad Bashey, MD<sup>5</sup>; H. Steven M. Devine, MD<sup>7</sup>; Hugo F. Fernandez, MD<sup>8</sup>; Sergio Giralt, MD<sup>9</sup>; Mehdi Hamadani, MD<sup>10</sup>; Alan Howard, MD<sup>11</sup>; Richard T. Maziarz, MD<sup>11</sup>; David L. Porter, MD<sup>12</sup>; Bart L. Scott, MD<sup>6</sup>; Erica D. Warlick, MD<sup>13</sup>; Marcelo C. Pasquini, MD<sup>14</sup>

## CLINICAL TRIALS AND OBSERVATIONS

## Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Joseph Bidele, MD<sup>1</sup>; Mehdi Hamadani, MD<sup>2,3</sup>; Peter Dawson, MD<sup>4</sup>; Michael Martinez, MD<sup>5</sup>; Asim M. Alavi, MD<sup>6</sup>; Madan Jagasia, MD<sup>7</sup>; Yusef A. Eftekhari, MD<sup>8</sup>

## CLINICAL TRIALS AND OBSERVATIONS

## Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

\*Claudio G. Brunstein,<sup>1</sup> \*Ephraim J. Fuchs,<sup>2</sup> Shelly L. Carter,<sup>3</sup> Chatchada Karanes,<sup>4</sup> Luciano J. Costa,<sup>5</sup> Juan Wu,<sup>6</sup> Steven M. Devine,<sup>6</sup> John R. Wingard,<sup>7</sup> Omar S. Aljaitawi,<sup>8</sup> Corey S. Cutler,<sup>9</sup> Madan H. Jagasia,<sup>10</sup> Karen K. Ballen,<sup>11</sup> Mary Eapen,<sup>12</sup> and †Paul V. O'Donnell,<sup>13</sup> on behalf of the Blood and Marrow Transplant Clinical Trials Network

<sup>1</sup>Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN; <sup>2</sup>Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD;

<sup>3</sup>The Emma Children's Hospital, Amsterdam, The Netherlands; <sup>4</sup>City of Hope National Medical Center, Duarte, CA; <sup>5</sup>Medical University of South Carolina, Charleston, SC; <sup>6</sup>The Ohio State University, Columbus, OH; <sup>7</sup>University of Maryland Medical System, Baltimore, MD; <sup>8</sup>University of Illinois at Chicago, Chicago, IL; <sup>9</sup>University of Texas MD Anderson Cancer Center, Houston, TX; <sup>10</sup>University of California, Los Angeles, Los Angeles, CA; <sup>11</sup>University of Michigan, Ann Arbor, MI; <sup>12</sup>University of Washington, Seattle, WA; <sup>13</sup>University of Texas at Austin, Austin, TX



## Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Bart L. Scott, Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steven M. Devine, David L. Porter, Richard T. Maziarz, Erica D. Warlick, Hugo F. Fernandez, Edwin P. Alyea, Mehdi Hamadani, Asad Bashey, Sergio Giralt, Marcelo C. Pasquini

## Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

## The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

OCTOBER 18, 2012

VOL. 367 NO. 16

## Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

Claudio Anasetti, M.D., Brent R. Logan, Ph.D., Stephanie J. Lee, M.D., M.P.H., Edmund K. Waller, M.D., Ph.D., Daniel J. Weisdorf, M.D., John R. Wingard, M.D., Corey S. Cutler, M.D., M.P.H., Peter Westerselt, M.D., Ph.D., Ann Woolfrey, M.D., Stephen Couban, M.D., G. Michael A. Pulsipher, M.D., David L. Porter, M.D., Paolo Anderlini, M.D., William I. Berenson, M.D., Christopher Bredeson, M.D., Shelly L. Carter, M.D., for the Blood and Marrow Transplant Clinical Trials Network

# >140 BMT CTN Publications